AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.370

+0.0100.42%

Volume:626.37K

Turnover:1.48M

Market Cap:3.07B

PE:-23.08

High:2.395

Open:2.390

Low:2.330

Close:2.360

52wk High:3.310

52wk Low:1.880

Shares:1.30B

Float Shares:786.49M

Volume Ratio:0.58

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.103

EPS(LYR):-0.118

ROE:-18.22%

ROA:-6.16%

PB:3.83

PE(LYR):-20.08

Loading ...

Overview Company News Filings

Mesoblast posts Ryoncil quarterly net sales of US$30.3 million

Ryoncil® Continues Successful First Year Launch With Net Sales of US$30.3M in March Quarter

THOMSON REUTERS

Mesoblast Ltd - Ryoncil Net Revenue for Quarter Increases to US$30.3M

THOMSON REUTERS

Mesoblast files Form 3 as director William Murray Burns reports beneficial ownership

Mesoblast CEO Silviu Itescu files initial beneficial ownership statement

Mesoblast files Form 3 initial beneficial ownership statement for director Gregory George

3 top ASX shares that could double in value from here

Mesoblast (ASX:MSB) Valuation Check As First R&D Day Puts Pipeline And Growth Plans In Focus

Simply Wall St.

2 battered ASX growth shares that could double in value or more

Mesoblast Director Philip James Facchina Files Initial Beneficial Ownership Statement

Mesoblast director Jane Catherine Bell files Form 3 initial beneficial ownership statement

Mesoblast names CFO James Michael O’Brien in initial beneficial ownership filing

Mesoblast names Chief Medical Officer and Director Eric Allen Rose in initial beneficial ownership filing

Mesoblast to host inaugural R&D Day webcast

Mesoblast Director George Gregory Files Initial Beneficial Ownership Statement

Is Mesoblast's New Clinical Leader Quietly Reframing Its Commercialization Story for Cell Therapies (ASX:MSB)?

Simply Wall St.

A Look At Mesoblast’s (ASX:MSB) Valuation As Leadership Changes Highlight Clinical Growth Plans

Simply Wall St.

Mesoblast appoints Teresa Montagut as Head of Clinical Development and Medical Affairs

DR. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

THOMSON REUTERS

Mesoblast Ltd-Appointment of Clinical Development and Medical Affairs Head

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/MSB.AU/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.37,"timestamp":1787536437641,"preClose":2.36,"halted":0,"volume":626366,"delay":0,"changeRate":0.004237288135593318,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.10268113798357884,"marketStatus":"Trading","change":0.01,"latestTime":"08-24 11:54:01 AEST","open":2.39,"high":2.395,"low":2.33,"amount":1480565,"amplitude":0.027542,"askPrice":2.38,"askSize":16507,"bidPrice":2.37,"bidSize":35016,"shortable":3,"etf":0,"ttmEps":-0.10268113798357884,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787551200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":2.36,"openAndCloseTimeList":[[1787529600000,1787551200000]],"volumeRatio":0.578043,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.36,"auctionPrice":2.39,"auctionVolume":3958,"auctionTime":1787529540683,"referenceTime":1787308204093,"auction":1,"marketStatus":"盘前竞价","timestamp":1787529540683}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-6.16%","roe":"-18.22%","lyrEps":-0.118008,"volumeRatio":0.578043,"shares":1296862776,"dividePrice":0,"high":2.395,"amplitude":0.027542,"preClose":2.36,"low":2.33,"week52Low":1.88,"pbRate":"3.83","psRate":"33.69","week52High":3.31,"institutionHeld":0,"latestPrice":2.37,"committee":0.359238,"eps":-0.10268113798357884,"divideRate":0,"volume":626366,"delay":0,"ttmEps":-0.10268113798357884,"open":2.39,"prevYearClose":2.72,"prevWeekClose":2.36,"prevMonthClose":2.05,"prevQuarterClose":1.955,"fiveDayClose":2.45,"twentyDayClose":2.14,"sixtyDayClose":2.14,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625983826","title":"Mesoblast posts Ryoncil quarterly net sales of US$30.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2625983826","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625983826?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:04","pubTimestamp":1775523873,"startTime":"0","endTime":"0","summary":"Mesoblast posted Ryoncil net sales of US$30.3 million for quarter ended March 31, 2026.Revenue in first year of launch approached US$100 million.February and March sales growth offset January holiday seasonality.Ryoncil revenue supported balance sheet strength, label expansion plans, late-stage development programs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDLvHm2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4585","NDAQ","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","BK7508","BK4112","LU2210149790.SGD","BK7501","BK4588","MSB.AU","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK7067","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625983849","title":"Ryoncil® Continues Successful First Year Launch With Net Sales of US$30.3M in March Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2625983849","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625983849?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:03","pubTimestamp":1775523838,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA3M92XP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MSB.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625998831","title":"Mesoblast Ltd - Ryoncil Net Revenue for Quarter Increases to US$30.3M","url":"https://stock-news.laohu8.com/highlight/detail?id=2625998831","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625998831?lang=en_us&edition=fundamental","pubTime":"2026-04-07 08:13","pubTimestamp":1775520794,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nFWN40P0N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MESO","BK7501","BK7067","BK7508","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624592351","title":"Mesoblast files Form 3 as director William Murray Burns reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2624592351","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624592351?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:27","pubTimestamp":1775039221,"startTime":"0","endTime":"0","summary":"Mesoblast director William Murray Burns filed an initial Form 3 disclosing 226,250 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL83gJyt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624592801","title":"Mesoblast CEO Silviu Itescu files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624592801","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624592801?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:25","pubTimestamp":1775039119,"startTime":"0","endTime":"0","summary":"Mesoblast CEO and Managing Director Silviu Itescu reported 78.96 million ordinary shares in an initial Form 3 filing dated March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL7LYPR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MSB.AU","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621503328","title":"Mesoblast files Form 3 initial beneficial ownership statement for director Gregory George","url":"https://stock-news.laohu8.com/highlight/detail?id=2621503328","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621503328?lang=en_us&edition=fundamental","pubTime":"2026-03-24 08:00","pubTimestamp":1774310455,"startTime":"0","endTime":"0","summary":"Mesoblast director George Gregory filed an initial beneficial ownership statement reporting 5 ordinary shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8thSHp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621744550","title":"3 top ASX shares that could double in value from here","url":"https://stock-news.laohu8.com/highlight/detail?id=2621744550","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621744550?lang=en_us&edition=fundamental","pubTime":"2026-03-23 06:27","pubTimestamp":1774218446,"startTime":"0","endTime":"0","summary":"It's been a rough stretch for some of the most talked-about ASX shares. But here's the twist: while share prices have slid or stalled, broker optimism hasn't. In fact, it's surging.Three ASX shares stand out right now: Mesoblast Ltd , Telix Pharmaceuticals Ltd , and Zip Co Ltd . All three have had turbulent months. Yet analysts see massive upside, in some cases, more than a double from here.This ASX share has had a shaky start to the year, with the share price down about 25%. That's nothing new for this high-risk biotech stock. Volatility comes with the territory.Analyst outlook: This is where things get interesting. Brokers have an average price target on the ASX share of $4.23 at the time of writing. That implies around 105% upside. In other words, analysts believe a doubling is firmly on the table if execution improves.Analyst outlook: Despite all that, brokers are highly optimistic. The average price target is $4.21. That's about 191% upside — nearly triple its current share price.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/23/3-top-asx-shares-that-could-double-in-value-from-here/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/23/3-top-asx-shares-that-could-double-in-value-from-here/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["TLX.AU","MSB.AU","BK7093","BK7501","ZIP.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620578889","title":"Mesoblast (ASX:MSB) Valuation Check As First R&D Day Puts Pipeline And Growth Plans In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2620578889","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620578889?lang=en_us&edition=fundamental","pubTime":"2026-03-20 13:10","pubTimestamp":1773983450,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) is drawing fresh attention after announcing its inaugural R&D Day in New York City on April 8, 2026. At the event, leadership and external experts will outline corporate strategy and pipeline plans.\nSee our latest analysis for Mesoblast.\nThose R&D Day plans come after a tough stretch for the share price, with a 30 day share price return of a 14.11% decline and a year to date share price return of a 25.27% decline, even though the three year total shareholder return is up...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-first-rd-day-puts-pipeli","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-first-rd-day-puts-pipeli","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7508","BK7067","BK4006","MSB.AU","MSB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620275862","title":"2 battered ASX growth shares that could double in value or more","url":"https://stock-news.laohu8.com/highlight/detail?id=2620275862","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620275862?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:00","pubTimestamp":1773946800,"startTime":"0","endTime":"0","summary":"It's been a bruising start to 2026 for many ASX growth shares, with some among the biggest victims of this year's market onslaught.Two names that stand out are Mesoblast Ltd  and Zip Co Ltd . At the time of writing, Mesoblast shares are down 23% year to date to $2.08, while Zip has plunged 52% to $1.48.By comparison theS&P/ASX 200 Indexhas shed 2.5% of its value so far this year.But after such steep declines for both ASX growth shares, could this be a classic buy the dip opportunity?This ASX growth share is no stranger to volatility, with its share price often swinging sharply on clinical updates and regulatory news.Even so, analysts remain optimistic on the ASX growth share, with an average 12-month price target of $4.23. This implies upside of around 104% from current levels.Rising interest rates, regulatory scrutiny, and concerns about consumer spending have all contributed to the sharp decline of the ASX growth share.After significant share price declines, they may be worth a close","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/20/2-battered-asx-growth-shares-that-could-double-in-value-or-more/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/20/2-battered-asx-growth-shares-that-could-double-in-value-or-more/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","BK7501","BK7067","BK7093","ZIP.AU","MSB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620251603","title":"Mesoblast Director Philip James Facchina Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251603","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251603?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:41","pubTimestamp":1773841317,"startTime":"0","endTime":"0","summary":"Philip James Facchina, a director of Mesoblast, filed an initial statement of beneficial ownership. The filing reported 123,220 ordinary shares held indirectly through HNP. It also listed director-held options covering 66,667 ordinary shares at an exercise price of AUD 2.26. Additional director-held options covered 96,811 ordinary shares at an exercise price of AUD 0.36. The filing reported indirect warrants through HNP for 68,306 ordinary shares at an exercise price of AUD 2.86.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5ctL40:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620251643","title":"Mesoblast director Jane Catherine Bell files Form 3 initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251643","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251643?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:40","pubTimestamp":1773841238,"startTime":"0","endTime":"0","summary":"Mesoblast director Jane Catherine Bell filed an initial statement of beneficial ownership. The filing reported 622,492 ordinary shares held indirectly via a self-managed superannuation fund. It also reported stock options to buy ordinary shares totaling 719,037 shares. The options carried exercise prices of AUD 0.36, AUD 0.83, and AUD 0.97.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5m0b48:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620251342","title":"Mesoblast names CFO James Michael O’Brien in initial beneficial ownership filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251342","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251342?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:35","pubTimestamp":1773840949,"startTime":"0","endTime":"0","summary":"Mesoblast reported an initial statement of beneficial ownership by James Michael O'Brien, its Chief Financial Officer. The filing stated that O'Brien beneficially owned no Mesoblast securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL64jXpp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7501","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620251348","title":"Mesoblast names Chief Medical Officer and Director Eric Allen Rose in initial beneficial ownership filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2620251348","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620251348?lang=en_us&edition=fundamental","pubTime":"2026-03-18 21:35","pubTimestamp":1773840903,"startTime":"0","endTime":"0","summary":"Mesoblast reported that Eric Allen Rose filed an initial statement of beneficial ownership as Chief Medical Officer and director. Rose reported direct ownership of 6,749,274 ordinary shares. He also reported options to buy 6,416,519 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL3HwLLB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","MSB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620401554","title":"Mesoblast to host inaugural R&D Day webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401554","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401554?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:20","pubTimestamp":1773789612,"startTime":"0","endTime":"0","summary":"Mesoblast will host an R&D Day on April 8, 2026 in New York City. The event is scheduled to run from 8:00am to 11:00am EST and will be webcast. The webcast link is .","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL6HbfW4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK7508","LU2095319765.USD","LU2210149790.SGD","BK7501","BK7067","IE00BKPKM429.USD","MSB.AU","SG9999014013.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","LU0314104364.USD","SG9999014039.USD","BK4588","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014021.USD","BK4112","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620497684","title":"Mesoblast Director George Gregory Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620497684","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620497684?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:07","pubTimestamp":1773698829,"startTime":"0","endTime":"0","summary":"Mesoblast reported an initial statement of beneficial ownership by director George Gregory. The filing listed indirect warrants for 6.83 million ordinary shares with an exercise price of USD 2.86. It also listed direct warrants for 200,000 ADS with an exercise price of USD 9.06. The filing also included direct options covering 66,667 ordinary shares with an exercise price of USD 1.72.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL8ctFfz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619412639","title":"Is Mesoblast's New Clinical Leader Quietly Reframing Its Commercialization Story for Cell Therapies (ASX:MSB)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2619412639","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619412639?lang=en_us&edition=fundamental","pubTime":"2026-03-14 15:37","pubTimestamp":1773473852,"startTime":"0","endTime":"0","summary":"Earlier this week, Mesoblast Limited created a new senior leadership role and appointed Teresa Montagut MD, PhD as Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Dr. Eric Rose, to lead medical affairs, clinical collaborations and investigator-initiated trials across its cell therapy programs.\nBy bringing in a physician-scientist with extensive experience in early pipeline studies and investigator-sponsored research at major biopharmaceutical companies,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblasts-new-clinical-leader-quietly-reframing-its-comm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblasts-new-clinical-leader-quietly-reframing-its-comm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK7508","BK7501","MSB.AU","BK7067","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618130978","title":"A Look At Mesoblast’s (ASX:MSB) Valuation As Leadership Changes Highlight Clinical Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130978","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618130978?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:27","pubTimestamp":1773322071,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has drawn fresh attention after appointing Teresa Montagut MD, PhD as Head of Clinical Development and Medical Affairs, a move that coincides with its upcoming Bell Potter Healthcare Horizons Summit presentation.\nSee our latest analysis for Mesoblast.\nThe recent appointment and upcoming summit appearance come after a tougher stretch for the share price, with a 30 day share price return of 14.4% and a 90 day share price return of 22.74%. However, the 3 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/a-look-at-mesoblasts-asxmsb-valuation-as-leadership-changes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/a-look-at-mesoblasts-asxmsb-valuation-as-leadership-changes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK7501","BK4006","MSB","MSB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618797413","title":"Mesoblast appoints Teresa Montagut as Head of Clinical Development and Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2618797413","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618797413?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271313,"startTime":"0","endTime":"0","summary":"Mesoblast appointed Teresa Montagut as Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Eric Rose. Montagut will lead the medical affairs organization and support investigator-initiated trials and clinical collaborations. She joined Mesoblast from Regeneron, where she was Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs for Investigator Sponsored Studies in gastrointestinal and genitourinary areas. Mesoblast said Montagut will support efforts to expand indications for its cell therapy programs in pediatric and adult inflammatory conditions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbkSytc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU0289739699.SGD","LU2468319806.SGD","LU0823434740.USD","REGN","LU0114720955.EUR","LU2362541513.USD","BK7508","SG9999014005.SGD","SG9999014013.SGD","LU2362540622.SGD","NDAQ","IE00BGHQF748.EUR","LU0320765992.SGD","LU0889565916.HKD","LU0053666078.USD","LU0314104364.USD","LU2089984988.USD","LU0882574055.USD","BK7067","LU0823434583.USD","LU2023250504.SGD","LU2210150020.SGD","LU2095319765.USD","BK4585","LU0058720904.USD","LU2237438978.USD","BK4139","LU2106854487.HKD","BK4588","LU0823416689.USD","LU1917777945.USD","SG9999014021.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK7501","MSB.AU","BK4112","IE00B3QW5Z07.USD","LU0109394709.USD","SG9999014039.USD","LU1974910355.USD","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618974134","title":"DR. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast","url":"https://stock-news.laohu8.com/highlight/detail?id=2618974134","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618974134?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271299,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA281YNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618882974","title":"Mesoblast Ltd-Appointment of Clinical Development and Medical Affairs Head","url":"https://stock-news.laohu8.com/highlight/detail?id=2618882974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618882974?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:58","pubTimestamp":1773269921,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUE4PZNBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","MSB.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":8,"totalSize":178,"code":"91000000","status":"200"}]}}